Jazz Pharmaceuticals (JAZZ) Deferred Taxes (2016 - 2025)
Jazz Pharmaceuticals has reported Deferred Taxes over the past 14 years, most recently at -$63.3 million for Q4 2025.
- Quarterly results put Deferred Taxes at -$63.3 million for Q4 2025, down 2588.28% from a year ago — trailing twelve months through Dec 2025 was -$445.0 million (down 113.59% YoY), and the annual figure for FY2025 was -$445.0 million, down 113.59%.
- Deferred Taxes for Q4 2025 was -$63.3 million at Jazz Pharmaceuticals, up from -$271.4 million in the prior quarter.
- Over the last five years, Deferred Taxes for JAZZ hit a ceiling of $190.7 million in Q2 2021 and a floor of -$271.4 million in Q3 2025.
- Median Deferred Taxes over the past 5 years was -$64.5 million (2022), compared with a mean of -$56.8 million.
- Biggest five-year swings in Deferred Taxes: soared 1114.78% in 2021 and later plummeted 2588.28% in 2025.
- Jazz Pharmaceuticals' Deferred Taxes stood at -$27.4 million in 2021, then crashed by 430.67% to -$145.4 million in 2022, then soared by 75.31% to -$35.9 million in 2023, then soared by 93.44% to -$2.4 million in 2024, then plummeted by 2588.28% to -$63.3 million in 2025.
- The last three reported values for Deferred Taxes were -$63.3 million (Q4 2025), -$271.4 million (Q3 2025), and -$66.4 million (Q2 2025) per Business Quant data.